Compare Merck & Co., Inc. (MRK) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs VanEck Semiconductor ETF — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while VanEck Semiconductor ETF trades at $570.66. The key difference: Merck & Co., Inc. pays a 2.3% dividend while VanEck Semiconductor ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SMH | |
|---|---|---|
Market Cap | $363.98B | — |
Sector | Health | — |
52-Week High | $156.43 | $668.91 |
52-Week Low | $77.60 | $300.83 |
Enterprise Value | $410.75B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SMH trades at $573.73, up 1.19% with a bullish technical outlook supported by moving averages and positive momentum indicators. The semiconductor ETF benefits from strong AI infrastructure demand, with recent NVIDIA earnings and industry expansion driving investor interest. Institutional activity shows continued accumulation, including a $678,000 position by Greenland Capital Management.
Outlook remains positive given AI-driven semiconductor demand, though risks include potential tariff impacts and market volatility. The ETF's diversified exposure to chip leaders offers growth potential while mitigating single-stock risk, supported by Wall Street's constructive stance on the sector's long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
